Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 13/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.63 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.63 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.63 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.63 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.63 |
| ▸ | FABP4 | P15090 | 1/20 | 0.59 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22720171 | 0.90 | TAS2R14 (0.74) | TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4 | |
| SCHEMBL6813056 | 0.88 | TAS2R14 (0.77) | TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4 | |
| SCHEMBL1358523 | 0.85 | TAS2R14 (0.75) | TAS2R14AKR1C3AKR1C2FABP4CLCN2 | |
| SCHEMBL6141544 | 0.80 | AKR1C3 (0.82) | TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4 | |
| SCHEMBL6141543 | 0.80 | AKR1C3 (0.82) | TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4 | |
| SCHEMBL4245559 | 0.79 | MAPK8 (0.67) | TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4 | |
| SCHEMBL6141415 | 0.79 | TAS2R14 (0.67) | TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4 | |
| SCHEMBL7592514 | 0.79 | TAS2R14 (0.70) | TAS2R14AKR1C3AKR1C2AKR1B1AKR1C4 | |
| Flufenamic Acid SCHEMBL29356958 | 0.78 | RXFP1 (0.75) | TAS2R14AKR1C3AKR1C2GRIK1ADRA2B | |
| Flufenamic Acid SCHEMBL17497 | 0.78 | RXFP1 (0.75) | TAS2R14AKR1C3AKR1C2GRIK1ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-05-21 | — | — | US | claimed |
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-05-21 | — | — | US | disclosed |
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-05-21 | — | — | US | disclosed |
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131527-A1 | NOVEL ANTHRANILIC ACID DERIVATIVES AND CHLORIDE CHANNEL BLOCKING AGENT CONTAINING THE SAME | CLIC1, ASIC1, CLIC4 | TAS2R14 1778/4885AKR1C3 787/4885AKR1C2 477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.